<p>Under the terms of the agreement, biopharmaceutical company Medarex and Organon plan to share development and commercialization responsibilities on any antibody-based therapeutics resulting from this collaboration, and to share revenues generated from the sale of such therapeutic products. Financial terms were not disclosed.<br /><br />David Nicholson, executive vice president of R&D at Organon, said: We have recently increased our efforts in Cambridge, Massachusetts, to identify novel biologicals which will be effective treatments for auto-immune and oncological disorders, this additional collaboration with Medarex represents a further step towards becoming a very effective biological drug hunting company.</p>